Investigation on coagulation activity, its inhibitors, and fibrinolysis in patients with colorectal cancer

Experimental Oncology

Volumn 25, Issue 3, 2003, Pages 216-220

  Szczepanski, M ^a   Nowacki, M ^b   Chwalinski, M ^b   Elbanowski, J ^a   Klukowski, M ^a   Grel, K ^c  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c Laboratory of Hemostasis   (Poland)

Author keywords

Coagulation inhibitors; Colorectal cancer; Fibrinolysis

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; PLASMIN; PROTEIN C; THROMBIN; BLOOD CLOTTING INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CANCER LOCALIZATION; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMINOGEN ACTIVATION;

EID: 0142023045     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954; 139: 846-52.
2. Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 1992; 18: 353-72.
3. Bloom AL. Physiology of blood coagulation. Haemostasis 1990; 20: 14-29.
4. Broze GJ Jr. Tissue factor pathway inhibitor. Haemostaseologie 1997; 17: 73-7.
5. Di Micco P, Romano M, Niglio A, Nozzolillo P, Federico A, Petronella P, Nunziata L, Di Micco B, Torella R. Alteration of haemostasis in non-metastatic gastric cancer. Digest Liver Dis 2001; 33: 546-50.
6. de Bruin PAF, Griffioen G, Verspaget JH, Lamers CBWH. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res 1987; 47: 4654-7.
7. Dvorak HF. Thrombosis and cancer. Human Pathology 1987; 18: 275-84.
8. Edwards RL, Rickles FR, Moritz TE, Henderson WG, Zacharski LR, Forman WR, Cornell CJ, Forcier RJ, O'Donnel JF, Headley E, Kim S-H, O'Dell R, Tornyos K, Kwaan HC. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987; 88: 596-602.
9. Ellis CN, Boggs HW, Slagle GW, Cole PA, Blakemore WS. Protein C activity, stage of disease and vascular thrombosis in colon carcinoma. Am J Surg 1992; 163: 78-81.
10. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001; 86: 51-6.
11. Falanga A, Barbui T, Rickles FR, Levine MN. Guidelines for clotting studies in cancer patients. Thromb Haemost 1993; 70: 540-2.
12. Ganesh S, Sier CFM, Griffioen G, Vloedgraven HJM, De Boer A, Welvaart K, van de Velde CJH, Van Krieken JHJM, Verheijen JH, Lamers CBWH, Verspaget HW. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 54: 4065-71.
13. Garcia-Avello A, Galindo-Alvarez J, Martinez-Melina E, Cesar-Perez J, Navarro JL. Coagulative system activation and fibrinolytic system inhibition activities arise from tumoral draining vein in colon carcinoma. Thromb Res 2001; 104: 421-5.
14. Gordon SG, Franks JJ, Lewis BJ. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res 1975; 6: 127-37.
15. Gordon SG. Cancer cell procoagulants and their role in malignant disease. Semin Thromb Hemost 1992; 18: 424-33.
16. Iversen N, Lindahl AK, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Brit J Haemat 1998; 102: 889-95.
17. Iversen LH, Thorlacius-Using O. Relationship of coagulation test abnormalities to tumor burden and postoperative DVT in resected colorectal cancer. Thromb Haemost 2002; 87: 402-8.
18. Iversen N, Lindahl AK, Abildgaard U. Elevated plasma levels of the factor Xa - TFPI complex in cancer patients. Thromb Res 2002; 105: 33-6.
19. Kirchheimer JC, Huber K, Wagner O, Binder BR. Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas. Brit J Haemat 1987; 66: 85-9.
20. Lindahl AK, Sandset PM. Abildgaard U, Andersson TR, Harbitz TB. High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chir Scand 1989; 155: 389-93.
21. Lindahl AK, Sandset PM, Abildgaard U. Indices of hypercoagulation in cancer as compared with those in acute inflammation and acute infarction. Haemostasis 1990; 20: 253-62.
22. Modrau IS, Iversen LH, Thorlacius-Using O. Hemostatic alterations in patients with benign and malignant colorectal disease during major abdominal surgery. Thromb Res 2001; 104: 309-15.
23. Montemurro P, Conese M, Altomare DF, Memeo V, Colucci M, Semeraro N. Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma. Int J Clin Lab Res 1995; 25: 195-200.
24. Nanninga PB, van Teunenbroek A, Veenhof CHN, Bueller HR, ten Cate JW. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer. Thromb Haemost 1990; 64: 361-4.
25. Norrheim L, Abildgaard U, Larsen ML, Lindahl AK. Involvement of the extrinsic pathway in the activities of low molecular weight heparin. Thromb Res 1991; 151: 19-27.
26. Sier CFM, Verspaget HW, Griffioen G, Verheijen JH, Quax PHA, Dooijeward G, de Bruin PAF, Lamers CBWH. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Gastroenterology 1991; 101: 1522-8.
27. Szczepański M, Bardadin K, Zawadzki J, Pypno W. Procoagulant activity of gastric, colorectal and renal cancer is factor VII-dependent. J Cancer Res Clin Oncol 1988; 114: 519-22.
28. van Duijnhoven EM, Lustermans FAT, van Wersch JWJ. Evaluation of the coagulation/fibrinolysis balance in patients with colorectal cancer. Haemostasis 1993; 23: 168-72.
29. Verspaget HW, Herheijen JH, de Bruin PAF, Griffioen G, Lamers CBWH. Plasminogen activators in (pre)malignant conditions of the colorectum. Eur J Cancer Clin Oncol 1989; 25: 565-9.
30. Vigano S, Manucei PM, D'Angelo A, Golfi C, Gensini GF, Rostagno C, Neri Semeri GG. Protein C antigen is not an acute phase reactant and is often high in ischemic heart disease and diabetes. Thromb Haemost 1984; 52: 263-6.
31. 2-antiplasmin complex in plasma samples by means of a radioimmunoassay. Scand J Clin Lab Invest 1983; 43: 27-33.
32. Zacharski LR, Wojtukiewicz MZ, Constantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemostas 1992; 18: 104-16.